RxDoctor Payments Data

Kathryn Richardson, NP

Nurse Practitioner · Modesto, CANPI 1215361589

Payments from drug & device makers

$4,076in general payments, 2019–2025

Across 217 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$600
  • Teva Pharmaceuticals USA, Inc.$575
  • AbbVie$546
  • Takeda Pharmaceuticals U.S.A., Inc.$533
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$319
  • Lundbeck LLC$313
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,91696%
  • Education$1604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,076 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$141,265
Medicare patients
273
Services billed
1,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate47$366,717
RexultiBrexpiprazole51$96,511
AustedoDeutetrabenazine11$76,523
VraylarCariprazine Hcl26$54,979
Lurasidone Hcl72$40,968
TrintellixVortioxetine Hydrobromide59$34,116
Effexor XrVenlafaxine Hcl11$21,352
CaplytaLumateperone Tosylate12$18,904
AuvelityDextromethorphan Hbr/Bupropion19$13,629
Hydroxyzine Hcl437$11,620
Quetiapine Fumarate362$10,900
Duloxetine Hcl376$9,355
BelsomraSuvorexant17$8,198
Bupropion XlBupropion Hcl180$7,755
Buspirone Hcl374$6,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$193$366,71747 claims
Otsuka America Pharmaceutical, Inc.Rexulti$175$96,51151 claims
Teva Pharmaceuticals USA, Inc.Austedo$575$76,52311 claims
AbbVieVraylar$546$54,97926 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$533$34,11659 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$319$18,90412 claims
Axsome Therapeutics, Inc.Auvelity$600$13,62919 claims
Lilly USA, LLCOlanzapine$125$5,240244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →